Brookline initiated coverage of Exelixis (EXEL) with a Buy rating.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis downgraded to Market Perform from Outperform at BMO Capital
- Exelixis partner Sairopa provides milestones update
- Exelixis downgraded to Neutral at BofA following 37% rally
- Exelixis downgraded to Neutral from Buy at BofA
- FDA tells Exelixis supplemental NDA for cabozantinib to be discussed in March